Polen Capital Management LLC raised its stake in shares of Celgene Corporation (NASDAQ:CELG) by 7.7% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,082,991 shares of the biopharmaceutical company’s stock after buying an additional 363,108 shares during the period. Celgene Corporation comprises about 5.8% of Polen Capital Management LLC’s investment portfolio, making the stock its 9th biggest holding. Polen Capital Management LLC owned 0.65% of Celgene Corporation worth $660,128,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently modified their holdings of CELG. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Celgene Corporation in the 1st quarter valued at $118,000. Motco lifted its stake in shares of Celgene Corporation by 19.3% in the 2nd quarter. Motco now owns 981 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 159 shares during the last quarter. Acropolis Investment Management LLC acquired a new stake in shares of Celgene Corporation in the 2nd quarter valued at $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its stake in shares of Celgene Corporation by 47.5% in the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock valued at $147,000 after purchasing an additional 380 shares during the last quarter. Finally, Rational Advisors LLC acquired a new stake in shares of Celgene Corporation in the 2nd quarter valued at $156,000. 79.16% of the stock is owned by institutional investors.
In related news, Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the sale, the director now directly owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the sale, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The disclosure for this sale can be found here. Over the last three months, insiders have sold 20,227 shares of company stock valued at $2,843,956. 0.95% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This piece of content was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another publication, it was stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/11/14/polen-capital-management-llc-raises-holdings-in-celgene-corporation-celg.html.
Celgene Corporation (NASDAQ CELG) opened at $101.16 on Tuesday. Celgene Corporation has a 12-month low of $94.55 and a 12-month high of $147.17. The stock has a market cap of $80,574.02, a P/E ratio of 15.99, a PEG ratio of 0.79 and a beta of 1.79. The company has a debt-to-equity ratio of 1.31, a quick ratio of 3.52 and a current ratio of 3.65.
Celgene Corporation (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. Celgene Corporation’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.58 earnings per share. research analysts anticipate that Celgene Corporation will post 6.67 EPS for the current fiscal year.
Several equities research analysts recently issued reports on the stock. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $175.00 price objective (up previously from $148.00) on shares of Celgene Corporation in a research note on Monday, July 31st. Cantor Fitzgerald set a $160.00 price objective on shares of Celgene Corporation and gave the company a “buy” rating in a research note on Thursday, July 27th. William Blair reaffirmed an “outperform” rating on shares of Celgene Corporation in a research note on Friday, October 20th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $160.00 price objective (up previously from $152.00) on shares of Celgene Corporation in a research note on Friday, July 28th. Finally, Leerink Swann reaffirmed a “buy” rating and issued a $156.00 price objective on shares of Celgene Corporation in a research note on Friday, October 20th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $139.64.
Celgene Corporation Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.